Objective: Our aim was to determine the frequency of skeletal metastasis in germ cell tumours (GCT) at baseline and at relapse on conventional Technetium-99m Methylene Diphosphonate (Tc-99m MDP) whole body bone scan (bone scan) and to evaluate the effect of bone metastases on survival.
Introduction:
Germ cell tumours (GCTs) are one of the commonest malignant tumours, comprising 1% of all the solid tumours in young male adults [1] . GCT usually metastasizes to retroperitoneal lymph nodes. Osseous metastases are a rare entity, particularly at primary diagnosis and its true incidence remains unknown. It is usually a late manifestation, with synchronous haematogenous spread to the lung, liver and brain and the overall prognosis of bone involvement is as poor as hepatic or CNS metastases [2] . Moreover, nonpulmonary metastases are considered poor prognosticators. For patients with metastatic GCT, prognostic factors at primary diagnosis are well recognised and the International Germ Cell Cancer Consensus Cooperative Group (IGCCCG) guidelines are followed to determine treatment regimens for chemotherapy. Bone metastases classifies patient into high risk (HR) (non seminomatous) group or intermediate risk (IR) (seminomatous) group [3] .
Conventional Technetium-99m Methylene Diphosphonate (Tc-99m MDP) whole body bone scan (bone scan), computerized tomography (CT) and magnetic resonance imaging (MRI) are various modalities for diagnosing bone metastases as indicated [4] . The incidence of osseous involvement, its responsiveness to chemotherapy and long-term prognosis remain poorly defined [5] .
Objective:
The main objectives of this study were: 1. To determine the frequency of skeletal metastases in patients with newly diagnosed GCT and/or relapsed after first-line chemotherapy. 2. To explore the characteristics, potential risk factors for skeletal metastases, and overall and disease free survival after chemotherapy in patients with and without bone metastases.
Material and methods:
Electronic medical records of 130 consecutive patients treated at our institution for histologically proven gonadal or extra-gonadal GCT between October 2010 and February 2016 were retrospectively analysed. All patients underwent Tc99m MDP bone scan as part of staging work up, or when relapse was suspected following initial highdose chemotherapy. Where suspicious, the osseous uptake on Tc-99m MDP bone scan was further correlated with additional radiological imaging. The association of bone metastases was assessed with gender, age, histopathology, stage and risk stratification according to IGCCC (International Germ Cell Consensus Classification) guidelines formulated in 1997 [3] , tumour marker elevation including Lactate Dehydrogenase / LDH (Normal =240-480 IU/L), Alpha fetoprotein / AFP (cut-off 10kU/L) and human chorionic gonadotropins / Β-HCG (cut-off 2U/L). Overall survival (OS), disease free survival (DFS) and treatment response was evaluated in patients with bone metastases at baseline and at relapse and compared to those without metastases and those with non osseous, visceral metastases.
Imaging:
Baseline Tc-99m MDP planar whole body bone scans were acquired 2.5 hours after the intravenous administration of Tc-99m MDP. Since 2013, a SPECT/CT scan was also acquired to better specify cause of uptake if needed. The scans were reported by experienced nuclear physicians. Bone involvement was diagnosed by radioisotope uptake. Foci of uptake were confirmed by one or more radiological imaging modality including plain radiograph, CT scan, MRI scan or 18F-FDG PET-CT as indicated clinically. HR and IR GCT were further evaluated for concurrent systemic metastasis. Chemotherapy was administered according to UKCCSG GCIII (Extracranial Germ Cell Tumour guidelines January 2011-Phase III Trial) protocol.
The institutional review board approved the study.
Statistical Analysis:
All the relevant statistical data was entered in SPSS software version. 20 (IBM, USA). Continuous variables were presented as mean or median with ranges. Categorical variables were presented as absolute and relevant frequencies. Correlative analysis was done using the chai-square or Log-rank test (categorical variables). A P<0.05 was considered statistically significant. Survival rates were analysed using the method of Kaplan-Meier (Kaplan and Meier 1958).
Results:
A total of 130 GCT patients underwent Tc-99m MDP bone scan between October 2010 and February 2016. Four were excluded due to incomplete information. Of the remaining 126, 59 (47%) were females and 67 (53%) were males. Mean age was 18 years (range: 1 month -72 years). 105 (83%) were of paediatric age group (under 18 years) at the time of initial diagnosis. Patient characteristics are summarized in Table 1 .
Characteristics of patients with bone metastases:
Overall, 9.5% (12/126) had bone metastases either at primary diagnosis or relapse. While classifying by the IGCCC guidelines, four (33%) had IR and eight (67%) had HR GCT. Of the 12 with bone metastases; five (42%) had mixed GCT, three (25%) yolk sac tumour, two (17%) immature teratoma and one each of seminoma (8%) and non-seminomatous GCT (8%). Tumour markers elevation of either LDH (lactate dehydrogenase) or AFP (α−fetoprotein) was seen in 92%. All the 12 were non β-HCG (β-human chorionic gonadotropins) secreting tumours. Bone metastases were found at diagnosis in seven and in five at relapse. Most frequent site of bone metastases was thoracolumbar spine (58%) with cord compression in 57% of them. Other sites included pelvis in 50%, ribs 42% and long bones in 42%. Bone metastases were solitary in 17% and multifocal in 83%. Clinically, 83% patients were symptomatic with localized bone pains.
In the seven with osseous metastases at baseline, additional sites of metastases included; lymph nodes (n=4), lung (n=2) and liver (n=1). In five with bone metastases at relapse, concomitant metastatic sites were; lymph node (n=4), lung (n=4) and liver (n=1). Table 2 outlines the risk category, treatment and outcome of patients with bone metastases. Tc-99m MDP bone scan findings were confirmed by CT scan in eight, MRI in six and radiograph in two. An MRI scan was used for assessing cord compression in four.
Treatment and outcome of patients with bone metastases:
42% of patients with bone metastases received only 1 st line chemotherapy, while 33% with progressive disease and relapse received additional 2 nd line and 25% 3 rd line chemotherapies. Table 2 outlines the chemotherapy regimens used and outcome of patients with bone metastases.
There was no significant correlation between the presence of bone metastases at diagnosis and the subsequent lines of chemotherapy received. Response assessment after chemotherapy showed stable disease in 33%, partial response with primary irresectable disease in 25% and progressive disease in 42%. One with partial response was lost to follow up. Neurological compromise was seen in the form of cord compression in four. In these patients, palliative management was done with lumber spine XRT in one and laminectomy in another. 
Characteristics of patients without bone metastases:
94% had no bone metastases at baseline. Out of these, 30% had low risk (LR)/stage I disease, 42% IR and 28% HR disease. Details of histological break up and tumour marker status of the 80 with IR and HR without bone metastases is in table 1. 24% patients had irresectable primary tumour site. Synchronous retroperitoneal/mediastinal nodal, pulmonary, hepatic and CNS metastases were seen in 59%, 27.5%, 15%, and 1% respectively at baseline staging.
Treatment and outcome of patients without bone metastases:
All stage I / LR were treated with complete resection of primary tumour only or followed by few cycles of systemic chemotherapy with subsequent surveillance with tumour markers. At the end of follow up, all were alive and disease free. XRT was given to four irresectable primary mediastinal/abdominal tumours, two with para-aortic nodal masses and one with brain metastases. 
Table1: Characteristics of GCT patients with or without bone metastases

Figure.1. Kaplan-Meier curve displaying the 5-year DFS in IR and HR GCT (No bone metastases, 63%
; bone metastases at baseline, 38% and bone metastases at relapse, 20%). The log-rank test showed a statistically significant difference in percent survival of patients with and without bone metastases both at baseline or relapse. ; bone metastases at baseline, 38% and bone metastases at relapse, 75%). The log-rank test showed a statistically significant difference in percent survival of patients with and without metastases at baseline (p=0.02).
Figure. 32.5% had disease relapse, out of which 16 had progressive disease, rest remained in remission. Seven (9%) were lost to follow up. 13 died with a median overall survival (OS) of 13 months (Range: 3-29 months); of these two died due to Bleomycin toxicity. The remaining 59% remained progression free with median OS of 21 months (range: 6 -60+ months). Ten with relapse remained in remission with median OS of 28 months (range: 11-60 months).
DFS and OS of patients with and without metastases:
Comparing those with bone metastases to those without metastases, the following correlations were found: By spearman's two-tailed test, patients with bone metastases had equal chance of presenting with visceral (lung, liver or both) metastases and various histologic subtypes as the difference was not statistically significant (p=0.06). On bivariate analysis, tumour histology (p=0.02), site of primary tumour (p<0.0001), the risk group (p=0.02), tumour resectibility status (p<0.001), presence of bone metastases at baseline (P<0.0001) and visceral involvement at baseline (p<0.0001) had significant influence on DFS and OS. Survival plots according to Kaplan-Meier curves are presented in Fig. 2 to 6 . Five year OS in the absence of bone metastases, with bone metastases at baseline and bone metastases at relapse was 77%, 38% and 75% respectively. The 5-year DFS for same cohort groups is 63%, 38% and 20% respectively.
Discussion:
Bone metastasis is a rare event in GCT, detected in 5% of patients at primary diagnosis [3] . Based on current treatment guidelines, the outcome of nonosseous metastatic GCT is good, achieving an overall cure rate of over 80% after standard chemotherapy. However, patient with osseous metastases achieve 5-years survival rate in range of 45-55% after cisplatin based combination chemotherapy [5, 7] . Although bone metastases are rare in GCT, prompt and accurate diagnosis is very crucial since there is significant treatment failure rate after 1 st line chemotherapy. Osseous metastases mainly affect young males and leads to morbidity in the form of pain and cord compression, necessitating use of radiotherapy in chemo-resistant cases [8] .
In routine practice, screening of bone metastases is generally not endorsed in adult cases of GCT.
Patients do not always present with bony symptoms related to metastases, they are usually detected incidentally on imaging. Hanjani et al. [2] found incidental bone metastases in 58%.
In our study, 83% of symptomatic patients had osseous metastases on Tc-99m MDP bone scans. Studies have suggested that back pain can be a manifestation of para-aortic lymphadenopathy [9] ; however consideration should always be given to metastatic disease especially if bone tenderness is present.
Hitchins et al. [5] report 3% incidence of bone metastases in gonadal and extra gonadal GCT at primary diagnosis and 9% at relapse with concomitant retroperitoneal and pulmonary metastases in all. Oechsle et al. [6] found primary bone metastases in 40/434 (9%) patients, with frequent histology of primary mediastinal tumours, yolk sac and synchronous liver metastases. In our study, 50% of non-seminomatous mediastinal GCT had bone metastases. In addition, 67% had retroperitoneal nodal diseases, 33% had synchronous lung metastases and 8.3% had lung and liver metastases, suggesting simultaneous lymphatic and haematological spread. Tumour markers elevation was more frequently seen in the presence of bone metastases (92%) as compared to the rest of study population (79%). Bokemeyer et al. [10] concluded that non-seminomatous histology, mediastinal primary site, presence of nonpulmonary visceral metastases, or marked elevation of serum tumour markers are poor prognosticators. In another study by Mead GM et al. [11] found a 3-year survival rate of 68% in 33% of patients with raised markers (either AFP>1000 kU/L or β-HCG >10,000 IU/L) among other poor prognostic factors versus 93% survival rate in 67% without raised markers. However, in our study none of the patients with bone metastases had HCG secreting features.
Although relapse in patients with primary bone metastases is less common than failure of cisplatin based chemotherapy leading to progressive disease. In our study, five patients with bone metastases died due to progressive disease less than one year after diagnosis. The 5-year OS of patients with bone disease at relapse was significantly better; 75% versus 38% in primary bone metastases. In our study, three patients had isolated bone metastases without synchronous nodal/visceral metastases, out of which one was a case of testicular seminoma rarely reported in literature [4, 12, 13, 14] . Seven patients with bone metastases did not respond to cisplatin based chemotherapy and were switched to 2 nd and 3 rd line regimens with radiotherapy to local disease sites. In addition to progression in bone metastases, relapse with new onset lung metastases in three and liver disease in one patient was seen. Two of these patients had isolated skeletal metastases at baseline with no extra skeletal disease. By the end of follow up, five died despite salvage treatment with a median survival of 9 months, one was stable with irresectable primary pelvic mass and one was lost to follow up. Hence the optimal treatment approach to bone metastases in patients with bone metastases remains elusive.
Limitations of this study are primarily related to the fact that data was gathered retrospectively. However since bone metastases in GCT are not frequent, prospective data collection would not be easy. We were able to reach meaningful outcomes from this data set. Our hospital did not have a SPECT/CT scanner before September 2013 therefore only planar scintigraphy was acquired prior to that and correlative radiologic imaging was performed separately where needed.
There were some variations in protocols over the course of this study. Since 2013, all patients underwent Tc-99m MDP bone scan, prior to that although most had bone scintigraphy, some who did not were excluded from this study.
Conclusion:
Skeletal metastases were found in 9.5% of GCT patients, 7.6% at baseline staging and 5.4% at relapse in IR or HR GCT. Based on our findings, baseline skeletal evaluation for metastases; especially in the presence of bone pain or known systemic metastases should be done because although skeletal relapses are rare, they have a dismal outcome. IGCCCG defined risk stratification, primary tumour resectibility and visceral metastases are better predictor of survival.
